Cargando…
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
Allo-HSCT is a curative therapy for hematologic malignancies owing to GvL effect mediated by alloreactive T cells; however, the same T cells also mediate GvHD, a severe side effect limiting the widespread application of allo-HSCT in clinics. Invariant natural killer T (iNKT) cells can ameliorate GvH...
Autores principales: | Li, Yan-Ruide, Zeng, Samuel, Dunn, Zachary Spencer, Zhou, Yang, Li, Zhe, Yu, Jiaji, Wang, Yu-Chen, Ku, Josh, Cook, Noah, Kramer, Adam, Yang, Lili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399487/ https://www.ncbi.nlm.nih.gov/pubmed/36034226 http://dx.doi.org/10.1016/j.isci.2022.104859 |
Ejemplares similares
-
Accumulation of T-cell-suppressive PD-L1(high) extracellular vesicles is associated with GvHD and might impact GvL efficacy
por: Baur, Rebecca, et al.
Publicado: (2023) -
Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015) -
Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022) -
Impaired thymic iNKT cell differentiation at early precursor stage in murine haploidentical bone marrow transplantation with GvHD
por: Zhao, Weijia, et al.
Publicado: (2023) -
Antibody- and aptamer-strategies for GvHD prevention
por: Oelkrug, Christopher, et al.
Publicado: (2015)